Chronic hemodialysis is implemented when irreversible loss of kidney function occurs. Sometimes renal recovery is overlooked. From January 2005 to December 2014, we identified 28 patients hemodialyzed for more than 3 months who had renal replacement therapy discontinued. The group consisted of 17 (57.7%) males and 11 (42.3%) females. Patients were 18-87 years old. Time of hemodialysis ranged from 3 to 97 months. Of note, 14 (50%) patients were referred from local dialysis units for solution of vascular access problems. In 13 (46.2%) patients dialysis was abandoned within the first 6 months, in 5 (17.8%) patients between 6 and 12 months, and in 10 (35.7%) patients beyond 12 months. Estimated dialysis-free survival was 94.4% (SE 0.054) and 82% (SE 0.095) at 12 and 24 months, respectively. All physicians must be aware of possible kidney function improvement. In patients with preserved diuresis fall in periodical urea or creatinine measurements might be a sign of renal recovery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hdi.12383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination of clinical frailty score and myostatin concentrations as mortality predictor in hemodialysis patients.
J Ren Nutr
January 2025
Departments of Nephrology - Dialysis - Transplantation, University of Liege, CHU de Liège, Liège, Belgium; Nephrology, Dialysis, Apheresis Unit, Centre Hospitalier Universitaire Caremeau, Nimes, University of Montpellier, Montpellier, France.
Background And Aims: Frailty is common among hemodialysis (HD) patients. Its assessment is usually based on clinical criteria. In the present work, we evaluated the interest of combining clinical frailty score and biomarkers to predict mortality of chronic HD patients.
View Article and Find Full Text PDFDepletion by Hemodialysis of the Antioxidant Ergothioneine.
Kidney360
November 2024
The Departments of Medicine, Veterans Affairs Palo Alto Healthcare System and Stanford University, Palo Alto, CA, USA 94304.
Background: Hemodialysis may excessively remove valuable solutes. Untargeted metabolomics data from a prior study suggested that ergothioneine was depleted in the plasma of hemodialysis subjects. Ergothioneine is a dietary-derived solute with antioxidant properties.
View Article and Find Full Text PDFImpact of nutritional status and pulmonary function on short- and long-term overall survival in hemodialysis patients.
PLoS One
January 2025
Department of Pulmonary Diseases, Uludag University Faculty of Medicine, Bursa, Turkey.
Background: End-stage renal disease (ESRD) patients frequently experience protein-energy wasting (PEW), which increases their morbidity and mortality rates.
Objective: This study explores the effects of nutritional status and pulmonary function on the short- and long-term mortality of ESRD patients undergoing hemodialysis.
Materials And Methods: 67 consecutive ESRD patients on maintenance hemodialysis were included in the study.
Supporting equitable access to kidney transplant in remote Western Australia using continuous quality improvement.
Int J Qual Health Care
January 2025
Kimberley Renal Services, PO Box 1377, Broome, Western Australia 6725, Australia.
Background: Despite an epidemic of end-stage kidney disease in the Australian Aboriginal and Torres Strait Islander population, disparities in access to kidney transplantation persist. The journey to a successful kidney transplant is long, with an initial suitability assessment required before waitlist-specific activities begin. In an Aboriginal Community Controlled renal service, we aimed to: (i) design and implement a continuous quality improvement (CQI) approach to transplant suitability assessment, (ii) provide transplant suitability assessments for all patients of the service, (iii) describe what temporary contraindications to kidney transplantation should be the focus of health service improvements, (iv) explore participant experiences with the suitability assessment process, and (v) use our findings to inform pre- and post-transplant model of care development within Kimberley Renal Services.
View Article and Find Full Text PDFVariable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1.
Pediatr Nephrol
January 2025
University Medical Center Hamburg-Eppendorf, University Children's Hospital, Martinistrasse 52, Hamburg, 20246, Germany.
Background: Primary hyperoxaluria type 1 (PH 1) is a rare genetic condition due to mutations in the AGXT gene. This leads to an overproduction of oxalate in the liver. Hyperoxaluria often causes kidney stones, nephrocalcinosis, and chronic kidney disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!